List view / Grid view
Scientists have evaluated mouse models used for developing treatments for mood disorders associated with Huntington's disease and have recommended which have greater potential for success.
The number of immuno-oncology active agents has seen a tremendous boost during the past three years. The 2019 global immuno-oncology pipeline consists of almost 3,900 agents, making immuno-oncology discovery very attractive.
VTP50469, a new targeted therapy for MLL-rearranged leukaemia, shows greater efficacy and fewer side-effects in mice, according to new research.
Researchers have found that damage to mitochondria due to sepsis may be the cause of muscle weakness in mice.
A new study has shown that a Class 1 CRISPR gene editing system can achieve functional DNA repairs in human cells with no prominent off-target effects.
This in-depth focus features articles on identifying new leads for neglected tropical diseases and how to develop novel peptide hits into lead compounds.
Scientists have used cryo-electron microscopy to clarify the structure of one of the key components of RSV and HMPV, which could lead to new therapies for the viruses.
Researchers have developed a novel peptide with a prolonged half-life that has demonstrated success in rhesus monkeys and mice for inhibiting HIV infections.
Isolated components found in the Saussurea controversa plant have antimicrobial and regenerative properties which could lead to a treatment for bone diseases.
A study has demonstrated that inducing brain vessel pulsations helps to clear substances from the brains of mice, so could be used to stop amyloid-β build up in the development of Alzheimer’s.
Researchers have identified the protein Annexin A6 as a potential therapeutical target against diseases that are caused by the accumulation of cholesterol and other lipids in endosomes.
Researchers have found that PGE2, a signalling molecule involved in inflammation, promotes colorectal cancer progression through a microRNA and targeting that microRNA could have therapeutic potential.
Researchers have found that soft tissue sarcoma cells stop a key metabolic process which allows them to spread and restarting that process could leave these cancers vulnerable treatments.
Scientists have developed a new method that accelerates the design and engineering of potential medicines and vaccines using glycosylation.
Therapeutic drugs based on biological materials (antibodies, hormones, cytokines, enzymes, fusion proteins) may have the ability to elicit an immune response in the host.
